Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 14/20 | 0.82 |
| ▸ | EGFR | P00533 | 5/20 | 0.75 |
| ▸ | INSR | P06213 | 3/20 | 0.65 |
| ▸ | IGF1R | P08069 | 3/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16752958 | 0.91 | ALK (1.00) | ALKEGFRINSR | |
| SCHEMBL29188606 | 0.90 | ALK (0.82) | ALKEGFRINSRIGF1RKCNH2 | |
| SCHEMBL26161575 | 0.87 | ALK (0.85) | ALKEGFRINSRIGF1RKCNH2 | |
| SCHEMBL29618204 | 0.87 | ALK (0.81) | ALKEGFRINSRIGF1RKCNH2 | |
| SCHEMBL30502344 | 0.86 | ALK (0.87) | ALKEGFRINSRIGF1RKCNH2 | |
| SCHEMBL21846999 | 0.85 | EGFR (1.00) | ALKEGFR | |
| SCHEMBL30180253 | 0.85 | ALK (0.85) | ALKEGFRINSRIGF1R | |
| SCHEMBL11916456 | 0.85 | ALK (0.85) | ALKEGFRINSRIGF1R | |
| SCHEMBL21846989 | 0.85 | EGFR (1.00) | ALKEGFR | |
| SCHEMBL31276403 | 0.85 | ALK (0.84) | ALKEGFRINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | ADRM1, VHL, MDM2 | ALK 5/4885EGFR 176/4885INSR 1929/4885 |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | ALK 5/4885EGFR 176/4885INSR 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.